TC Biopharm reports first patient remission in Cohort B after TCB008 treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2025
0mins
Patient Treatment Success: TC BioPharm reported that the first patient in Cohort B, who had detectable Minimal Residual Disease (MRD), achieved complete molecular remission after receiving their lead drug candidate TCB008, with a total of approximately 500 million gamma delta t-cells administered over two weeks.
Significance of the Milestone: This achievement marks a significant milestone for TC BioPharm in developing innovative cell therapies aimed at effectively targeting and eradicating malignant cells, addressing the challenges faced by over 1 million patients diagnosed with blood cancers annually.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
